Ultrasensitive ctDNA testing distinguishes patients with very different risks for recurrence — but it remains to be seen whether acting on the results can improve their outcomes.

A new study has revealed a promising new approach to curb the spread of triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of the disease. Published recently in ...

Ten years after tailored radiotherapy (RT) for breast cancer, fewer than 3% of patients had locoregional recurrences (LRR), ...

Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific ...

In this episode of The OncoloGIST, breast cancer oncologist and clinical researcher Dr Paolo Tarantino of Dana-Farber Cancer ...

Scientists at HSE University have identified a molecular mechanism underlying aggressive breast cancer. They found that the signals supporting tumour growth originate not from the tumour itself but ...

In a subgroup of black women enrolled in a US breast cancer registry called BEST, women deemed to have low-risk tumours using the MammaPrint test had a 97.7% recurrence-free rate after 10 years, the ...

Researchers at the CU Anschutz Cancer Center have discovered how breast cancer cells that spread to the lungs may take ...

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA. We are at a critical crossroads for the clinical use of ctDNA ...

Ataraxis AI, a frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, today announced ...

Learn how breast cancer cells exploit healing processes in the lungs to support tumor growth and what this means for ...

Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer can predict whether they are likely to ...